Phase II trial of carboplatin in patients with advanced melanoma Journal Article

  


Authors: Casper, E. S.; Bajorin, D.
Article Title: Phase II trial of carboplatin in patients with advanced melanoma
Abstract: We report the results of a phase II evaluation of carboplatin (CBDCA) in 45 patients with advanced malignant melanoma. Of the 43 evaluable patients, 6 had been treated previously with chemotherapy; 11 had been treated with immunotherapy. The initial dose was 400 mg/m2 i.v. every 4 weeks; the dose was modified as required to achieve moderate myelosuppression. There was one complete response (duration 16 months) and six partial responses, for a major objective response rate of 16%. Toxicity consisted primarily of acute nausea and vomiting, and thrombocytopenia. The activity of CBDCA in this disease is similar to that of cisplatin and dacarbazine. © 1990 Kluwer Academic Publishers.
Keywords: adult; clinical article; aged; advanced cancer; antineoplastic agents; combined modality therapy; palliative care; carboplatin; interleukin 2; melanoma; metastasis; phase 2 clinical trial; nausea; thrombocytopenia; vomiting; neoplasm metastasis; organoplatinum compounds; infusions, intravenous; clinical trials; intravenous drug administration; middle age; drug evaluation; human; male; female; priority journal; article; support, u.s. gov't, p.h.s.
Journal Title: Investigational New Drugs
Volume: 8
Issue: 2
ISSN: 0167-6997
Publisher: Springer  
Date Published: 1990-05-01
Start Page: 187
End Page: 190
Language: English
DOI: 10.1007/bf00177256
PUBMED: 1696568
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025280313&doi=10.1007%2fBF00177256&partnerID=40&md5=34b3c740db4f4e3ef34209f8ae3dacb2
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Dean Bajorin
    657 Bajorin
  2. Ephraim S Casper
    108 Casper
Related MSK Work